NFKB1 and myelodysplastic syndrome: These results demonstrated that the NF-κB pathway inhibition by nanodrug in vivo lowered the tumor infiltration of M2 TAMs and MDS, which in turn promoted the recruitment of CD8+ T cells to the tumor.